BC Innovations | Oct 24, 2019
Distillery Therapeutics

Combined PTP-1B and PTPN2 inhibition for weight loss in obesity

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity Combined inhibition of PTP-1B and PTPN2, which regulate leptin and insulin signaling, could promote weight loss in obese patients. In mice with high fat diet-induced obesity, knockout of both targets...
BC Innovations | Jun 26, 2019
Distillery Therapeutics

Inhibiting PTP-1B to improve islet graft outcomes for Type I diabetes

DISEASE CATEGORY: Endocrine/metabolic; transplant INDICATION: Diabetes; islet cell transplant Inhibition of PTP-1B in pancreatic islet cell grafts could help improve outcomes in Type I diabetes. In a mouse model of Type I diabetes, knockout of...
BC Week In Review | Jul 13, 2018
Clinical News

Cold Harbor JV developing copper chelator for Wilson's disease

DepYmed Inc., a joint venture between Cold Spring Harbor Laboratory and Ohr Pharmaceutical Inc. (NASDAQ:OHRP), is developing its protein tyrosine phosphatase 1B (PTP-1B; PTPN1) inhibitor DPM-1001 as a copper chelator for Wilson's disease. In a...
Items per page:
1 - 3 of 3